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Improved standardization and robustness of particle-based therapies is required to 
translate promising new biotechnologies to the clinic. In particular, more precise control 
over particle size, monodispersity, and batch-to-batch homogeneity are needed. A 
microfluidic technology was developed to enable polymeric microparticle synthesis with a 
narrow size distribution and improved control over particle sizes. Key parameters including 
microfluidic channel size, polymer solvent, polymer concentration, and microfluidic flow 
rates were independently investigated and characterized. By engineering these parameters 
in particle synthesis, monodisperse polymeric microparticles with tunable sizes were 
successfully produced. To demonstrate the utility of these monodisperse polymeric 
particles for use as a therapeutic, next-generation biomimetic artificial antigen presenting 
cells (aAPCs) were fabricated. Monodisperse PLGA microparticles were first synthesized 
in the new microfluidic devices and then functionalized with proteins to create aAPCs. 
Microfluidic preparation of the microparticles enhanced surface conjugation of presented 
proteins, and the particles were also demonstrated to have the capacity for sustained release 
of a loaded drug. These precisely controllable polymeric particles of micron-size have 
promise for applications ranging from drug delivery vehicles to devices for cellular 
immunoengineering. The microfluidic continuous manufacture method of polymeric 
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Introduction to the thesis 
1.1 Cancer Immunotherapies 
Cancer is a leading cause of death and is a major focus for pharmaceutical and 
biotechnological studies and therapeutic development. Various cancer therapies including 
surgeries[1], radiotherapies[2], chemotherapies[3], hormone therapies[4] and 
immunotherapies[5] have been well developed. Among the therapies, immunotherapy is 
one of the newest and hottest research areas. One of the early demonstrations of utilizing a 
person’s own immune system to fight cancer dates back to the 1980s when William Coley, 
a young New York surgeon, began intratumoral injection of live or inactivated 
Streptococcus pyogenes and Serratia marcescens in an effort to reproduce the spontaneous 
remissions of sarcomas observed in rare-cancer patients who had developed erysipelas[6]. 
As part of its normal function, the immune system detects and destroys abnormal cells, 
including cells that turn into carcinoma. Researchers have found that patients with tumor-
infiltrating lymphocytes (TILs), immune cells that are found in and around tumors, often 
have a better life expectancy[7]. 
However, cancer cells inherently have the ability to evade monitoring by the 
immune system through genetic changes that make them less visible, create surface 
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proteins that turn off immune cells, and/or changing the normal cells around the tumor to 
create an immunosuppressive microenvironment. The major aim of immunotherapy is to 
facilitate the endogenous immune system to destroy tumor cells to treat cancers (Figure 
1.1). Several types of immunotherapies are used to treat cancer, including immune 
checkpoint blockade[8], T cell transfer therapy[9], monoclonal antibodies[10], and cancer 
vaccines[11]. 
Adaptive anti-tumor immune responses must begin with the capture of tumor 
associated antigens by antigen presenting cells (APCs) such as dendritic cells. To promote 
the antigen presentation functions of APCs and the production of tumor-specific T cell 
responses, researchers found that polymeric particle-based synthetic artificial antigen 
presenting cells (aAPCs) proved to be an effective platform for T cell activation[12, 13]. 
Further evaluation and characterization of key physical and chemical parameters of aAPCs 
including size, material composition, shape and surface characteristics could improve 
aAPC function for T cell activation. 
 
1.2 Polymeric particles based on poly(lactic-co-glycolic acid) 
Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed 
biodegradable polymers. PLGA, whose hydrolysis products are lactic acid and glycolic 
acid that can be metabolized by the body via the Krebs cycle, has minimal systemic toxicity 
and has been clinically approved by the US FDA to be used in various drug delivery 
systems[14] (Figure 1.2). By changing the composition of the co-polymer, the degradation 
time is tunable from several months to several years[15], and PLGA is commercially 
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available with different molecular weights and co-polymer compositions. The surface of 
PLGA particles is easy to modify, for example, by PEGylation (coating with a hydrophilic 
polyethylene glycol (PEG) layer at the surface)[16] or conjugating proteins at the 
surface[12]. The synthesis method of PLGA particles is easy to set up and modify[12, 17]. 
The most common technique is the emulsification-solvent evaporation technique (single 
emulsion). In this technique, PLGA (and hydrophobic payloads) are dissolved in an organic 
solvent (dichloromethane) and the emulsion, oil (O) in water (W) i.e. O/W, is prepared by 
adding water and a surfactant (e.g. poly(vinyl alcohol) (PVA)) to the polymer solution. The 
nano- or micro-sized droplets are induced by sonication or homogenization. The solvent is 
then evaporated and the particles are collected after washing. A modification of this 
technique is called double emulsion, which is used to encapsulate hydrophilic drugs (e.g., 
peptides and proteins) by adding a first W/O emulsion step before the O/W emulsion. The 
first emulsion step of the combined W/O/W allows hydrophilic payloads dissolved in water 
to form droplets in PLGA solutions that then subsequently form PLGA-containing droplets 
in a larger aqueous solution. These characteristics make PLGA particles attractive as 
versatile platforms for drug delivery, theranostics and vaccines. 
The sizes[18], shapes[12], and surfaces[19] of PLGA particles have been 
engineered and well investigated. However, there is a general lack of precise control over 
particle size and often large polydispersity in particle size during fabrication following 
conventional production methods. This creates a challenge to setting standards for particle-
based therapies, makes it more difficult for good manufacturing practices, and adds a 
significant barrier between bench-top research and its translation to the clinic. Renewed 
efforts to precisely control particle sizes and narrow particle size distributions of PLGA 
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particles can promote the safe and effective clinical application of more sophisticated 
biotechnologies and nanomedicine that build upon fundamental particle designs.  
 
1.3 Microfluidic droplet generators 
Microfluidics has been described as the science and technology of systems handling 
small volumes of fluids using micron-sized channels[18]. Microfluidic devices for the 
generation of microdroplets have led to many applications spanning the food, cosmetic, 
and pharmaceutical industries, particularly to go beyond the limits of traditionally used 
emulsification techniques[20-22]. By classifying the internal geometry of channels, 
microdroplet generators can be categorized into coflowing devices (Figure 1.3a), in which 
the continuous and discontinuous phases (i.e., liquids that will form the emulsion) flow in 
the same direction at the junction; (ii) flow-focusing devices (Figure 1.3b), in which the 
continuous phase flows from two opposite channels and perpendicularly to the 
discontinuous phase flow; and (iii) T-junction devices (Figure 1.3c), that are similar to the 
flow-focusing devices except that the continuous phase flows from a single channel. The 
microfluidic emulsion permits the entrapment of sensitive or poorly water-soluble 
molecules under soft conditions[23] to generate highly monodisperse droplets (CV lower 
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Fig. 1.1. Generation and regulation of antitumor immunity[25]. Understanding the 
events in generating and regulating antitumor immunity suggests at least three sites for 
therapeutic intervention: promoting the antigen presentation functions of dendritic cells, 
promoting the production of protective T-cell responses, and overcoming 












Fig. 1.2. Hydrolysis of PLGA[14]. Hydrolysis products of PLGA are lactic acid and 












Fig. 1.3. Different designs of microfluidic droplets generators[26]. (a) co-flow device, 








This project investigated the effects of different parameters in microfluidic flow 
focusing devices (MFFDs) to fabricate poly(lactic-co-glycolic acid) (PLGA) 
microparticles with differentially tuned particle sizes and low polydispersity in particle size 
for function as therapeutics. The effect of polymer solvent, concentration, flow rates and 
channel sizes of microfluidic devices on particle sizes was evaluated. Subsequently, 
biological cell-sized PLGA microparticles were synthesized and functionalized as artificial 
antigen presenting cells (aAPCs). Broader application of the microfluidic emulsion method 
to different materials and emulsifications are presented to demonstrate the potential use of 
MFFDs as a versatile platform for monodisperse particle synthesis. 
 
2.2 Specific Aims 
Specific Aim 1. Evaluate the effects of microfluidic device parameters on PLGA 
microparticle size, polydispersity, and morphology. 
Aim 1A. To evaluate the effect of polymer solvent in microfluidic devices on 
PLGA microparticle morphology. 
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Aim 1B. To evaluate the effect of polymer concentration in microfluidic devices 
on particle size of PLGA microparticles. 
Aim 1C. To evaluate the effect of microfluidic device channel size on particle size 
of PLGA microparticles. 
Aim 1D. To evaluate the effect of flow rates within microfluidic devices on particle 
size of PLGA microparticles. 
 
Specific Aim 2. Create monodisperse biodegradable artificial antigen presenting cells 
(aAPCs). 
Aim 2A. Prepare monodisperse PLGA microparticles and evaluate the conjugation 
of T cell activation proteins to the particle surface to create aAPCs. 
Aim 2B. Prepare monodisperse PLGA-based aAPCs with an encapsulated 
immunoregulatory drug, SD-208, and evaluate encapsulation and sustained release of the 
loaded aAPCs. 
 
Specific Aim 3. Evaluate broader applications of microfluidic emulsion to different 
materials and emulsifications. 
Aim 3A. Investigate the use of microfluidic emulsion for poly(β-amino ester) 
(PBAE)-PLGA blend particles. 





Synthesis of monodisperse artificial antigen 
presenting cells with tunable sizes 
3.1 Introduction 
Cancer immunotherapy is drawing increased attention for treatment of various 
cancers such as leukemia[1], melanoma[2], renal cell cancer[3], non-small cell lung 
cancer[4] and a growing list of other cancers due to impressive and durable response rates. 
Besides CAR-T therapies and checkpoint blockade therapies, which have shown 
substantial efficacy in the clinic[5, 6], various preclinical studies demonstrate other 
promising immunotherapy approaches. Biomimetic artificial antigen presenting cells 
(aAPCs) can be a promising platform for T cell activation and immune system 
modulation[7-9]. Artificial antigen presenting cells interact with and activate naïve T cells 
by displaying T cell activation proteins, usually anti-CD3 or peptide-loaded MHC (signal 
1) and co-stimulatory anti-CD28 (signal 2), on the surface of micro- or nanoparticles. The 
particle-based immune activation strategy provides a platform for complementary 
approaches, such as using small molecule drugs to modulate intracellular signaling 
pathways to increase potency and/or increasing the durability of immune-mediated tumor 
regression from cancer immunotherapies[10-14]. Small molecule transforming growth 
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factor beta (TGF-beta) inhibitor SD-208 is a great example of a promising small molecule 
drug for immunotherapy[15]. TGF-beta is a generally immunosuppressive cytokine that is 
usually overexpressed by tumor cells, inhibiting immune cell proliferation and effective 
function[16]. Targeted delivery of TGF-beta inhibitors to CD8+ T lymphocytes show 
efficacy in reversing TGF-beta signaling[15]. As there are known effects of particle 
size[17], material [18-22] and shape[8, 9] on aAPC efficacy at activating T cells, more 
progress is needed in controlling the large batch-to-batch variability often observed in 
aAPC manufacture. Typical existing procedures of micro- and nanoparticles production 
use bulk emulsion via sonication or mechanical homogenization to generate polymeric 
particulate materials[8], in which the oil phase containing polymer solution is disturbed in 
the aqueous phase containing surfactant as a stabilizer. Large polydispersity makes it hard 
to standardize particle-based therapies, setting a significant barrier for translational 
application of bench-top research to the clinic. In addition, the upper-end of many particle 
size distributions can contain large particles that, though relatively few in number, could 
cause blockage of capillaries following in vivo administration. Furthermore, the potential 
overlap in particle size distributions between differently designed batches obscures precise 
study of the effects of particles size on the efficacy of particle-based therapies. 
Microfluidic droplet generators, used in quick diagnosis[23, 24], single cell 
analysis[25], and cell encapsulation[26], can inherently generate monodispersed droplets. 
Studies show that microfluidic devices can produce monodisperse polymeric particles of 
micron-scale sizes[27-29], providing a low-cost and easy-to-use platform for 
emulsification. The commonly used droplet generating microfluidic devices include co-
flow devices, T-junction devices[30] and flow focusing devices[26]. Flow focusing devices 
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have been used to synthesize photocurable polymeric particles[29, 31], ion-crosslinkable 
thermosensitive gels[32], polymer-encapsulated cells[33], and other particles[27]. In 
previous studies, the drug release kinetics from the particles generated by microfluidic 
devices was well studied[31]. However, the application of monodisperse microparticles to 
immune engineering and the comparison between the efficacy of aAPCs based on 
monodisperse particles rather than polydisperse particles has not been well-studied. To 
enhance efficacy, safety, reproducibility, and scale-up, it would be interesting to evaluate 
aAPCs fabricated via classic bulk emulsion compared to aAPCs fabricated via microfluidic 
devices. 
In this chapter, we describe the fabrication of monodisperse, biodegradable, SD-
208-loaded microparticles and functionalization of these particles into aAPCs. Our 
objective in this research was to demonstrate the manufacture of monodisperse and scalable 
aAPCs and to compare them to bulk-emulsion aAPCs. We hypothesize that monodisperse 
microparticles made by microfluidic flow focusing devices may have improved efficacy 
and utility as aAPCs. 
 
3.2 Materials and Methods 
Fabrication of microfluidic devices: We fabricated the microfluidic channels using soft 
lithography[37]. The height of each device was 100 mm. We sealed the plasma-oxidized 
PDMS mold against an oxidized glass slide (Corning); it was necessary to plasma oxidize 
the surfaces of both the PDMS and the glass before bringing them into contact to make 
covalent bonds[33]. In order to avoid the wetting of the dispersed phase to the inner surface 
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of the device and to induce stable hydrophilicity of the channel walls[34], a pretreatment 
of the channels was performed by prefilling the channels with 1% PVA (25kDa) (Sigma 
Aldrich; St. Louis, MO) solution for 30 minutes and washing out the PVA via air blowing 
and heat drying immediately after sealing the PDMS mold to the glass slide. 
 
Fabrication of PLGA monodisperse microparticles using microfluidic devices: We 
followed reported procedures to synthesize PLGA microparticles using microfluidic flow 
focusing devices (MFFDs)[28]. Briefly, poly (lactic-co-glycolic acid) acid terminated (38-
54 kDa, 50:50 L:G ratio) (PLGA, Sigma Aldrich; St. Louis, MO) was used as the core 
material for particle synthesis. The PLGA was dissolved at desired concentrations in 
dichloromethane (DCM) or ethyl-acetate to form the dispersed phase solution in the 
MFFDs. For SD-208 drug release studies, particles were loaded with SD-208 (Cayman 
Chemical; Ann Arbor, MI) at a 10% mass ratio (wt/wt) of the drug to the polymer. Teflon 
tubing (Cole Parmer; Vernon Hills, IL) was used to connect the syringe and inlets on the 
device. Automatic syringe pumps (Cole Parmer, Vernon Hills, IL) were used to provide 
steady flow rates for both the dispersed phase and continuous phase. For the studies on the 
effects of dispersed phase solvent, PLGA was dissolved in DCM or ethyl acetate at 20 
mg/mL. MFFDs with 50 m channel size were used and the flow rates of dispersed phase 
and continuous phase was set at 1 mL/hr and 10 mL/hr, respectively. For the studies on the 
effects of polymer concentration on particle sizes, PLGA was dissolved at 2 mg/mL, 10 
mg/mL and 20 mg/mL, respectively, in DCM. MFFDs with 100 m channel size were used 
and the flow rates of dispersed phase and continuous phase was set at 1 mL/hr and 10 
mL/hr, respectively. For the study on the effects of channel sizes on particle sizes, MFFDs 
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with 100 m and 50 m channel sizes were used. For these studies, two different sets of 
parameters were used: PLGA was dissolved at 20 mg/mL in DCM and the flow rates of 
dispersed phase and continuous phase was set to 1 mL/hr and 10 mL/hr, respectively; 
PLGA was dissolved at 2 mg/mL in DCM and the flow rates of dispersed phase and 
continuous phase was set to 0.5 mL/hr and 15 mL/hr, respectively. For the study of effects 
of flow rate ratio on particle sizes, PLGA was dissolved at 2 mg/mL in DCM. MFFDs with 
100 m channel size were used and the flow rate of dispersed phase was set to 0.5 mL/hr 
as a constant. For these experiments, the flow rate of the continuous phase was varied to 
be either 5 mL/hr, 10 mL/hr, or 15 mL/hr, respectively. Droplets were collected in a 250 
mL beaker prefilled with 50 mL of continuous phase solution on a stir plate. The buffer in 
the collecting beaker was stirred while collecting particle droplets to minimize potential 
aggregation. The generated droplets were incubated in the beaker overnight to allow the 
dispersed phase solvent to evaporate and the particles to harden. The particles were then 
washed three times with deionized water at 3,200 g for 5 minutes, frozen and lyophilized. 
 
Bulk PLGA microparticle synthesis: Polymeric nanoparticles were synthesized using 
single emulsion techniques as previously described[8, 38]. PLGA was dissolved at 20 
mg/mL in DCM and 5 mL of the polymer solution was then emulsified in 50 mL of 1% 
polyvinyl alcohol (PVA) solution using a homogenizer (IKA-3725001; Wilmington, NC) 
set to 3.2k rpm for 1 minute. The resulting emulsification was poured into 100 mL of a 0.5% 
PVA solution on a magnetic stir plate at 500 rpm and the particles were allowed to harden 
for at least 4 hours. The particles were centrifuged at 3200 g for 5 minutes to pellet out 
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microparticles. The supernatant was collected and washed three times with deionized water 
at 40,000 g for 15 minutes, frozen and lyophilized. 
 
Protein conjugation: EDC-NHS chemistry was used to conjugate T cell-binding and 
activation proteins anti-CD3 and anti-CD28 onto the surface of monodisperse PLGA 
microparticles made by MFFDs. The conjugation procedures were modified based on 
established methods[8]. The particles were briefly incubated in 1 M NaOH solution (pH 
~14) to degrade the surface and expose additional carboxylic acid groups on the surface. 1 
N HCl solution (pH~0.1) was added to quench the pre-degradation. The particles were 
incubated in 4-morpholinoethanesulfonic acid (MES) buffer containing 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 
(sulfo-NHS) for 30 minutes. Then, Syrian hamster anti-mouse-CD28 (Clone 37.51, 
BioLegend; San Diego, CA) in 100 L 1X PBS was added at a dose of 10 g per mg 
particles. After a 3-hour reaction with anti-CD28, rat anti-mouse-CD3 (Clone 17A2, 
BioLegend; San Diego, CA) was added at a dose of 8 g per mg particles. After an 
overnight reaction between the antibodies and microparticles, the microparticles were 
washed three times to remove the residual free antibodies that did not attach to the 
microparticles. In order to quantify the amount of anti-CD3 and anti-CD28 antibodies on 
the surface of the particles, Alexa FluorTM 488 labeled anti-rat antibody and Alexa FluorTM 
647 labeled anti-hamster antibody were used (BioLegend; San Diego, CA). Particles were 
incubated with a cocktail of two antibodies for 30 minutes at room temperature in 1X PBS 
at 2 mg/mL of each antibody. Following incubation, the particles were washed three times 
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in 1X PBS at 3,200 g for 5 minutes and read on a BioTek Synergy 2 plate reader (BioTek; 
Winooski, VT). 
 
SD-208 release studies: Two mg of the particles loaded with SD-208 were dissolved in 1 
mL Dimethyl sulfoxide (DMSO) to quantify the encapsulation efficiency. The absorbance 
at 570 nm was measured on a BioTek Synergy 2 plate reader (BioTek; Winooski, VT). In 
order to characterize drug release profile, SD-208 loaded particles were incubated in 1X 
PBS at 2 mg/mL. On days 1, 2, 3, 4, 8 and 12, the particles were centrifuged at 3,200 g for 
5 minutes to pellet out microparticles. The supernatant was collected and the absorbance 
measured on a BioTek Synergy 2 plate reader (BioTek; Winooski, VT). 
 
Characterization of PLGA microparticles: Microparticles made by bulk emulsion and 
MFFDs were imaged under scanning electron microscopy (SEM) using a LEO/Zeiss Field-
emission SEM. The sizes of microparticles were measured manually using ImageJ[39]. 
 
Statistics: All experiments were performed with n = 3 replicates unless otherwise stated. 
Bar graphs indicate mean ± standard error of the mean. n.s. (not significant) indicates p > 
0.05, * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001, and **** 
indicates p ≤ 0.0001. All statistics were completed using statistical analysis software 
modules in GraphPad Prism 8 (GraphPad Software, Inc.; La Jolla, CA). For particle size 
measurements, a Student’s t-test was used to assess the difference between particles made 
by MFFDs of different channel sizes. Student’s t-test was also used in the comparison 
between PLGA microparticles made by bulk emulsion and monodisperse microparticles 
20 
 
made by MFFDs. In all cases, differences were considered significant if the p-value of the 
test was less than 0.05. 
3.3 Results 
3.3.1 The effect of polymer solvent on microparticle morphology 
We used flow focusing droplet generator to produce monodisperse microparticles. 
In a flow focusing design, the dispersed phase is introduced directly into the main channel 
while the continuous phase is injected and divided into two branches placed 
perpendicularly[28]. The dispersed phase, which is polymer in its solvent, is then pinched 
on both sides by the continuous phase, which is water with surfactant to prevent particle 
aggregation, and a droplet is formed due to the competition between the viscous forces and 
the surface tension at the interface between the two phases. The successful operation of 
flow focusing devices relies on hydrophilicity of the channel walls[31]. However, 
polydimethylsiloxane (PDMS), which allows easy manufacture of microfluidic devices, is 
inherently hydrophobic. Thus, a dispersed phase containing PLGA would eventually wet 
the sidewall of PDMS devices, preventing the formation of discrete droplets and thus 
particles and limiting the durability of such a device. Therefore, to induce stable 
hydrophilicity of the channel walls[34], a pretreating methods was used by prefilling the 
channels with a 1% PVA solution and washing out the PVA via air blowing and heat drying. 
In order to operate our microfluidic devices to produce monodisperse 
microparticles, we followed previously reported methods[28]. Briefly, 
polytetrafluoroethylene (PTFE) tubing connected the syringe and inlets on the device. 
Automatic syringe pumps were used to provide steady flow rate for both the dispersed 
21 
 
phase and the continuous phase. Droplets were collected in a beaker prefilled with 
continuous phase solution on a stir plate (Figure 3.1). The buffer in the collecting beaker 
was stirred while collecting the particles to minimize potential aggregation. The generated 
droplets were incubated in the beaker overnight to allow the dispersed phase solvent to 
evaporate. The particles were then centrifuged, washed three times with water, and 
lyophilized to generate dried microspheres. 
We used two different polymer solvents to dissolve PLGA and compared the 
morphologic characteristics of particles prepared from each method. Dichloromethane 
(DCM) was used as a traditional solvent for PLGA nano- and micro- particle production. 
PLGA was dissolved in DCM in 20 mg/mL as the dispersed phase for use in our 
microfluidic devices. 1% PVA water solution was used as continuous phase. The flow rates 
of dispersed phase and continuous phase was kept constant. The obtained PLGA 
microparticles were imaged under the scanning electron microscopy (SEM) to characterize 
the size and monodispersity of the particles. 
Although DCM is generally viewed as a good polymer solvent that is widely used 
in polymeric particle synthesis, the inherent hydrophobicity was found to wet the channel 
walls of the microfluidic device, preventing consistent production of monodisperse 
microparticles and decreasing the durability of the devices. It has been reported that some 
partially water-miscible solvents such as ethyl-acetate can be used for polymeric nano- and 
micro- particle synthesis as well[35]. The partial water miscibility of ethyl acetate 
decreases the occurrence of hydrophobic wetting of the dispersed phase solution when used 
as PLGA solvent in microfluidic flow focusing devices. 
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We used the same parameters (PLGA concentration, flow rate, and channel size) as 
to compare the shapes of microparticles produced from ethyl acetate as the dispersed phase 
compared to DCM. SEM images showed that the PLGA microparticles produced with 
DCM as the dispersed phase were spherical (Figure 3.2), like the microparticles made by 
traditional bulk emulsion (Figure 3.3). The PLGA microparticles produced by ethyl acetate 
as the dispersed phase, however, had a dimple shape with a indentation in the center of 
each disk instead (Figure 3.4). 
A possible reason for the anisotropic shape is that ethyl acetate has a lower volatility 
than dichloromethane, and ethyl-acetate will evaporate more slowly during the formation 
of microparticles. The formation of microparticles requires the polymer solvent that 
composes the emulsion droplets to diffuse to the water-droplet interface and evaporate[36]. 
Subsequently, the increased concentration of polymer within a smaller droplet will cause 
the separation of solvent and polymer and the hardening of the polymeric particles. The 
smaller evaporation speed of ethyl acetate makes the hardening of PLGA particles occur 
more slowly. With the slower diffusion and evaporation of ethyl acetate, PLGA 
accumulates at the solvent-water interface and solidifies. As phase separation occurs, a 
PLGA shell forms. However, the solvent (ethyl acetate) that remains in the droplets has to 
be released. Under the effects of gravity, the upper part of the newly formed PLGA shell 
is the most fragile section of the polymer shell. The remaining solvent can break this upper 
part of the shell to release from the droplet, and thus the dimple forms. 
Although ethyl acetate as a PLGA solvent can prolong the durability of microfluidic 
flow focusing devices, it inevitably makes the microparticles form an anisotropic dimple 
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shape. Due the forces driving the dimple formation, the larger the gravitational influence 
and the larger the microparticle size, the more pronounced the dimple shape they will be. 
 
3.3.2 The effects of polymer concentration on microparticle size and 
monodispersity 
As the ethyl acetate solvent will cause microparticles to be dimple-shaped, we used 
dichloromethane as the solvent so that the spherical microparticles can have a controlled, 
isotropic shape. Microparticles were produced following the same procedures using  
microfluidic flow focusing devices as described above. We used PLGA in DCM at 
different concentrations as the dispersed phase and 1% PVA in water as the continuous 
phase. The other parameters, including flow rates and the design of the MFFDs, was 
maintained constant.  SEM imaging was used to image the produced microparticles to 
measure the effects of polymer concentration on the size and polydispersity of the particles. 
Here we induce a parameter, coefficient of variation (CV), to quantify the 
polydispersity of microparticles, which is defined as the ratio between the standard 
deviation and the mean of the particle diameter multiplied by 100. The particle diameters 
of the microparticles were quantified manually after imaging via SEM. The monodisperse 
PLGA microparticles were found to have a small CV of approximately 5%. As comparison, 
we also made PLGA microparticles via typical bulk emulsion and imaged the particles via 
SEM. The microparticles fabricated by bulk emulsion had a CV up to 30%. Different 
PLGA concentrations used in the preparation of the PLGA microparticles did not change 
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the monodispersity of produced microparticles significantly, and the CV remained 
approximately 5% (Table 3.1). 
However, by using MFFDs of the same design and channel size, as the PLGA 
concentration increases, the particle sizes of the microparticles increases (Table 3.1 and 
Figure 3.5). The increase in microparticle sizes can be interpreted as the result of increased 
polymer concentration in the formed droplet. The increased amount of PLGA contained in 
each droplet causes the hardened microparticle formed by each droplet to be larger. Good 
reproducibility was found using the microfluidic flow focusing devices to produce droplets 
and particles of the desired size, with PLGA concentration being an important parameter 
to tune particle size while maintaining monodispersity. 
 
3.3.3 The effect of channel size on microparticle size and monodispersity 
Similarly to the study of the effects of polymer concentration on microparticle sizes 
and monodispersity, we used PLGA in DCM as the dispersed phase and a 1% PVA solution 
as continuous phase to investigate the role of channel size. Here we chose the parameters 
that previously generated relatively large particles and used microfluidic flow focusing 
devices of two different channel sizes to explore the role of channel size, focusing on the 
size of the channel at the intersection of the continuous phase and the dispersed phase. 
After SEM imaging and quantifying the sizes and polydispersity of the images, the 
generated microparticles were found to maintain good monodispersity in both of the groups 
studied. We observed similar monodispersity between the two channel sizes for 
microparticle production and the CV of the microparticles produced was approximately 5% 
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(Table 3.2), consistent with the study above. Using the same polymer concentration and 
flow rate, the microparticles made by the MFFD with the larger channel produced larger 
particle sizes compared with the particles that the smaller sized channel produced (Table 
3.2 and Figure 3.6). 
However, when we subsequently used another set of parameters (higher continuous 
phase flow rate and lower dispersed phase flow rate to make smaller particles) to repeat the 
experiment, we found that channel size has a limited ability to tune particle size smaller 
beyond a critical size threshold. The new device parameters were set to produce smaller 
microparticles and the MFFDs of the same design with two different channel sizes were 
used. The results showed that the monodispersity of the microparticles was consistent with 
CVs of 5% (Table 3.3). However, with these new device settings there was not a significant 
difference between the particle sizes of the microparticles produced using MFFDs of the 
two different channel sizes (Table 3.3, Figure 3.7 and Figure 3.8).  
The observed phenomena is likely due to relative length scales between the droplet 
size and the channel size. Generally, for larger microparticles, a smaller channel size 
decreases the sizes of the droplets (and subsequent microparticles) that the device makes. 
However, due to flow conditions the generated droplets are significantly smaller than both 
sizes of the channels, as in the second experiment, the channel sizes have limited influence 




3.3.4 The effects of flow rate ratio on microparticle size and 
monodispersity 
The effects of polymer concentration and channel size of microfluidic flow 
focusing devices on microparticle size and monodispersity were studied above. To make 
the devices more versatile to produce particles of different size, the parameter that is the 
easiest for a user to tune is the flow rate. The flow rate can be manipulated by changing the 
setting of the syringe pumps rather than by fabricating different devices or preparing 
PLGA-DCM solutions of different concentrations. To study the effects of flow rate 
(especially the flow rate ratio of the dispersed phase to the continuous phase), we kept 
parameters other than flow rates constant. First, the flow rate of the dispersed phase was 
set constant and the flow rate of the continuous phase was manipulated. 
The results of SEM imaging and image quantification revealed that when the flow 
rate of the dispersed phase remained unchanged, by changing the flow rate of the 
continuous phase the generated monodisperse microparticle had different size, with higher 
flow rates leading to smaller particle size (Figure 3.9). As before, the monodispersity 
remained low with a CV of approximately 5% (Table 3.4). 
In summary, by tuning certain key parameters during particle production, including 
the channel size of MFFDs, the flow rate ratio of the dispersed phase to the continuous 
phase, and concentration of PLGA in the dispersed phase, we obtained microparticles of 
different tunable sizes (from ~7 m to ~50 m), and the polydispersity remained low 
regardless of microparticle size (CV ~5%) (Table 3.5). While large microparticles are 
typically desired for drug delivery depots due to their large drug loading capacity, we 
desired to engineer small, monodisperse microparticles that were approximately the same 
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size as biologic cells and capable of multiple routes of in vivo administration[1]. By 
engineering MFFDs and tuning multiple fabrication parameters, consistent monodisperse 
isotropic microparticles of biomimetic size were successfully generated. 
 
3.3.5 In vitro drug release and protein conjugation 
Among the library of monodisperse microparticles of different sizes, we selected 
cell-sized, small microparticles (monodisperse microparticles of 7 m) to be further 
investigated, as these sized particles match the classical design of aAPCs and allow for 
multiple modes of administration in vivo. It has been reported that the smallest capillaries 
in adults are approximately 7 m [40]. A larger spherical particle means a larger surface 
area to present proteins to interact with T cells as well as a larger volume to encapsulate 
and release immunomodulatory molecules, both properties capable of boosting the efficacy 
of aAPCs. Thus, an ideal particle size range for aAPC design is at or just under this smallest 
capillary limit.  
In order to functionalize the monodisperse microparticles, T cell-binding and 
activation proteins, anti-CD3 as signal 1 and anti-CD28 as signal 2, were conjugated on 
the surface of particles via EDC-NHS[8]. Briefly, the particles were incubated in 4-
morpholinoethanesulfonic acid (MES) buffer containing 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 
(sulfo-NHS). Then a cocktail of mouse anti-CD3 and anti-CD28 was added and the 
antibodies and microparticles reacted overnight before washing out the residual free 
antibodies that did not become conjugated to the microparticles. Fluorescent secondary 
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antibodies were used to quantify the protein amount of each protein on the surface. The 
fluorescence was measured via a fluorescence plate reader. 
Low protein conjugation was observed on the surface of the microparticles 
following the conventional EDC-NHS conjugation procedure (Figure 3.10). The low 
conjugation efficiency was likely a result of residual PVA surfactant coating on the surface 
of the microparticles following microfluidic fabrication. Such a coating could cover the 
reactive carboxylic acid surface groups and hinder the formation of linkages between 
carboxyls on the particle surface and amines on the proteins. In addition, we also observed 
more anti-CD3 protein on the surface after conjugation than anti-CD28 protein. Therefore, 
we next modified the coupling procedure such that we first incubated the microparticles in 
a NaOH solution to degrade the particle surface and expose more carboxylic acid groups. 
For coupling, anti-CD28 protein in PBS buffer was firstly added to the particles and given 
a 3-hour incubation time alone before anti-CD3 protein was subsequently added to the 
reaction. As before, protein coupling was quantified by  secondary fluorescent antibodies 
and a fluorescence plate reader. 
Compared with the original conjugation procedure, the modified conjugation 
procedure improved conjugation efficiency, increased amount of both proteins on the 
surface, and improved the ratio of the two proteins to be closer to unity (Figure 3.11). 
Further, the monodisperse microfluidically-prepared microparticles also had a higher 
amount of both proteins conjugated to their surface compared with microparticles of 
similar size fabricated by conventional bulk emulsion (Figure 3.12). The molar ratio of 
anti-CD3 (signal 1) to anti-CD28 (signal 2) was approximately 1, as desired, indicating a 
relatively equal amount of two signals necessary for T cell activation.  
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To boost potential T cell activation function further and to break a potentially 
immunosuppressive microenvironment, we also incorporated SD-208[15], which is a 
hydrophobic small molecule TGF-beta inhibitor, into the microparticles. To quantify drug 
encapsulation, we dissolved the drug loaded particles and measured the absorbance of SD-
208. The results show approximately 80% efficiency of the added drug being successfully 
loaded into the particles (Figure 3.13). In general, the drug was released from the PLGA 
microparticles in a sustained manner (Figure 3.14), in accordance with literature 
describing similar release of small hydrophobic drug molecules from PLGA particles[28]. 
 
3.4 Conclusion and Discussion 
In this work, polymeric microparticles of tunable size with excellent 
monodispersity, reproducibility, and scalability have been developed through microfluidic 
flow focusing devices. Further, we have successfully demonstrated that monodisperse 
biodegradable polymeric microparticles of cell-like biomimetic size can be successfully 
functionalized as artificial antigen presenting cells (aAPCs) by the conjugation of a signal 
1 and signal 2 to the surface and can also encapsulate and release immunomodulatory 
molecules. Through modification of microfluidic flow focusing device parameters such as 
polymer concentration, flow rate ratio of the dispersed to continuous phases, and channel 
sizes of the devices, we have demonstrated the ability to tune particle size by approximately 
an order of magnitude while maintaining excellent monodispersity. To demonstrate proof-
of-concept, we functionalized monodisperse microparticles made by the devices into 
biomimetic aAPCs by conjugating T cell activation proteins anti-CD3 and anti-CD28 on 
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the surface and incorporating the small molecule immunomodulatory drug SD-208 into the 
particles. In addition to narrow size distribution and scalability, our monodisperse 
microparticles exhibit increased protein conjugation efficiency compared with 
microparticles prepared by bulk emulsion. The low variability between batches in synthesis 
makes it possible to standardize the particle-based therapies as drug delivery vehicles and 
as aAPCs. The continuous manufacturing methods are easily scalable by simply running 
the devices for a longer time, unlike with batch manufacturing methods. Future directions 
to enhance biomimicry would likely further improve aAPC function including double 
emulsion methods using microfluidic devices for encapsulation of hydrophilic proteins, 
continued investigation into particle shape, and exploration of broader materials for aAPC 
construction. Overall, these methods demonstrate a versatile and translatable approach 
towards the manufacture of precise monodisperse microparticles for immunoengineering, 
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Table 3.1. PLGA microparticle size and polydispersity as a function of polymer 
concentration and manufacturing procedure. By using MFFDs of the same design and 
channel size, as the PLGA concentration increases from 2 mg/mL to 20 mg/mL, the size 
of microparticles increases from 20 m to 50 m, with particles demonstrating excellent 












Table 3.2. PLGA microparticle size and polydispersity as a function of channel size 
in microfluidic devices for large particles. By using MFFDs of the same design, 
polymer concentration and flow rate, the smaller sized channel (50 m) generated smaller 
microparticles with an average size of 30 m compared to a larger size 100 m channel 
that generated 51 m-sized particles. All of the particles had excellent monodispersity 











Table 3.3. PLGA microparticle size and polydispersity as a function of channel size 
in microfluidic devices for small particles. By using MFFDs of the same design, 
polymer concentration and flow rate, to create smaller sized particles an order of 
magnitude reduced in comparison to channel size, channel size by itself was found to not 
significantly influence particle size. With the smaller channel 50 m size, particle size 













Table 3.4. PLGA microparticle size and polydispersity as a function of flow rate 
ratio. The results of SEM imaging and quantitative image analysis showed that when the 
flow rate of the dispersed phase remained at 0.5 mL/hr, by tuning the flow rate of the 
continuous phase between 5 mL/hr, 10 mL/hr and 15 mL/hr, the generated monodisperse 
microparticle had average sizes of 22 m, 13 m and 7.5 m. The polydispersity 












Table 3.5. Summary of PLGA microparticle size and polydispersity from different 
manufacturing methods. The size and polydispersity of microparticles can be tuned by 
key parameters of MFFDs and CV of all microfluidic preparations are superior to bulk 












Fig. 3.1. Schematic of the microfluidic flow focusing device set up and fabrication of 













Fig. 3.2. SEM image of PLGA microparticles fabricated with dichloromethane. The 
monodisperse microparticles are fabricated by microfluidic flow focusing devices with 
dichloromethane as the polymer solvent and are of similar size and have spherical 











Fig. 3.3. SEM image of PLGA microparticles fabricated with ethyl acetate. The 
monodisperse microparticles fabricated by microfluidic flow focusing devices with ethyl 
acetate as the polymer solvent are of similar sizes but have “dimple” morphology as seen 












Fig. 3.4. SEM image of PLGA microparticles prepared by bulk emulsion. The 
microparticles fabricated by bulk emulsion with dichloromethane as the polymer solvent 











Fig. 3.5. Size distribution of PLGA microparticles as a function of polymer 
concentration. As the polymer concentration decreases from 20 mg/mL to 2 mg/mL, the 
sizes of the microparticles decrease from approximately 50 m to 20 m. All 
microparticles fabricated by MFFDs have a narrow size distribution relative to their mean 











Fig. 3.6. Size distribution of large PLGA microparticles as a function of channel 
size. When the parameters were chose to generate larger particles (PLGA concentration 
was 20 mg/mL, flow rate of continuous phase is 10 mL/hr and flow rate of dispersed 
phase is 1 mL/hr), as the channel size of microfluidic flow focusing devices decreases, 
the sizes of larger microparticles decrease from approximately 50 m to 30 m. All 













Fig. 3.7. Size distribution of small PLGA microparticles as a function of channel 
size. When the parameters were chose to generate smaller particles (PLGA concentration 
was 2 mg/mL, flow rate of continuous phase is 15 mL/hr and flow rate of dispersed phase 
is 0.5 mL/hr), the sizes of smaller microparticles is not affected by channel size of 
microfluidic flow focusing devices. All microparticles made by MFFDs are 











Fig. 3.8. Size of different microparticles. When the parameters were chose to generate 
smaller particles (PLGA concentration was 2 mg/mL, flow rate of continuous phase is 15 
mL/hr and flow rate of dispersed phase is 0.5 mL/hr), as the channel size of microfluidic 












Fig. 3.9. Size distribution of PLGA microparticles as a function of flow rate. When 
the flow rate of the dispersed phase is maintained at 0.5 mL/hr, as flow rate of the 
continuous phase increases, the size of microparticles decreases.  All microparticles made 
by MFFDs have a narrow monodisperse size distribution compared with microparticles 










Fig. 3.10. Protein conjugation by EDC-NHS chemistry with standard conditions. By 
EDC-NHS chemistry, we obtain a relatively low amount of proteins conjugated on the 
surface of PLGA microparticles. There is also more anti-CD3 protein conjugated on the 
particles than anti-CD28 protein. Low dose refers to using 4 g anti-CD3 and 5 g anti-












Fig. 3.11. Protein conjugation by EDC-NHS chemistry with enhanced conditions. By 
pre-degradation of the particle surface and sequential addition of anti-CD28 protein first 
and then anti-CD3 protein during conjugation, improved protein conjugation was 
achieved with higher amount of proteins on the surface and a balanced molar ratio of the 











Fig. 3.12. Protein conjugation by EDC-NHS chemistry. By modified EDC-NHS 
chemistry, monodisperse PLGA microparticles made by MFFDs have higher conjugation 













Fig. 3.13. Release profile of SD-208 from PLGA microparticles fabricated by a 












Fig. 3.14. Drug loading and encapsulation efficiency of SD-208 into monodisperse 





Microfluidic emulsions of PLGA/PBAE 
polymer blends  
4.1 Introduction 
Microfluidic flow focusing devices described above are ideally used to generate 
single emulsion polymeric microparticles with high uniformity in size[1]. Single emulsions 
enable the formation of oil-in-water (O/W) and encapsulation of hydrophobic drugs in the 
particles. To deliver other hydrophilic payloads like peptides, proteins, and nucleic acids, 
a modified emulsification procedure called double emulsion (water-in-oil-in-water, 
(W/O/W)) is needed[2]. The application of microfluidic flow focusing devices (MFFDs) 
with our design could be extended to perform a W/O emulsion and a W/O/W double 
emulsion. A W/O first step followed by the O/W emulsion step previously described could 
enable the fabrication of monodisperse double emulsion polymeric microparticles and 
would broaden the utility of MFFDs. 
In the construction of aAPCs, poly(lactic-co-glycolic acid) (PLGA) microparticles 
demonstrated lower than desired protein conjugation efficiency in the previously discussed 
experiments and new materials, such as polymer blends, could potentially improve protein 
conjugation. Poly(β-amino acid)s (PBAEs) are a class of cationic polymers that are used 
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by researchers as gene delivery vectors[3] or protein delivery vehicles[4]. PBAEs are 
particularly advantageous for therapeutic use because they are biodegradable via 
hydrolysis of their ester linkages. PLGA-PBAE blend particles showed high efficiency in 
protein and nucleic acid delivery[5] while maintaining the capacity of PLGA particles to 
slowly degrade and controllably release loaded drugs[6]. However, the ability of 
microfluidic flow focusing devices (MFFDs) to fabricate PLGA-PBAE microparticles and 
engineer control over particle size has not been previously investigated. Fabrication of 
scalable monodisperse PLGA-PBAE microparticles of defined size could enable enhanced 
delivery properties and facilitate the evaluation of other blended microparticles with well-
defined physical properties. 
In this chapter, we investigated the potential of MFFDs to fabricate monodisperse 
W/O emulsion droplets, monodisperse PLGA-PBAE blend microparticles, and 
functionalization of PLGA-PBAE particles into enhanced artificial antigen presenting cells 
(aAPCs). Our objective in this research is to broaden the application of MFFDs and to 
show the potential of MFFDs to be versatile platforms for particle synthesis using varied 
biomaterials. 
 
4.2 Materials and Methods 
Fabrications of microfluidic devices: The fabrication of microfluidic channels for PLGA-
PBAE microparticle synthesis was the same as described in the methods for microfluidic 
device fabrication in Chapter 3. To fabricate microfluidic channels for W/O emulsion, we 
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bound polydimethylsiloxane (PDMS) molds on PDMS flat sheets after plasma-oxidizing 
the surfaces directly and without pretreatment of PVA. 
 
Generation of water droplets in oil (W/O): The physical microfluidic device setup was the 
same as used to fabricate PLGA microparticles as described in Chapter 3. Instead of using 
PLGA in DCM as the dispersed phase and a PVA solution as continuous phase (for O/W 
in Chapter 3), we used 10% PVA solution as the dispersed phase and DCM as the 
continuous phase. To avoid aggregation of droplets, the generated droplets were collected 
in a beaker containing the continuous oil phase of DCM (5 mL) with the surfactants Span 
80 (100 mg) and Tween 80 (33 mg) under magnetic stirring[7]. The droplets were imaged 
under optical microscopy. 
 
Fabrication of PLGA-PBAE monodisperse microparticles using microfluidic devices: We 
followed the equipment set up for microparticle fabrication as described in Chapter 3. The 
PBAE we used was poly(1,4-butanediol diacrylate-co-4,4’-trimethylenedepiperidine) (B4-
SP). The synthesis of B4-SP polymer by Michael addition was performed as described in 
the literature[8]. 4,4’-trimethylenedipiperidine (SP) (Sigma Aldrich; St Louis, MO) was 
dissolved in THF at 500 mg/mL and added to neat 1,4-butanediol diacrylate (B4) (Sigma 
Aldrich; St Louis, MO) at a 1.05:1 molar ratio (B4:SP). The mixture was stirred 2 days at 
50°C. Synthesized polymer was stored as a solution in THF at -20°C. 75% w/w of PLGA 
and 25% w/w of B4-SP were mixed and dissolved in dichloromethane (DCM) at a 
concentration of 2 mg/mL. We used the parameters that fabricated 7-8 m PLGA 
microparticles to generate PLGA-PBAE blend particles: the flow rate of the dispersed 
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phase and the continuous phase was 0.5 ml/hr and 15 ml/hr, respectively, and the channel 
size of the MFFDs was 50 m. Droplets were collected in a 250 mL beaker prefilled with 
50 mL of continuous phase solution on a stir plate. The generated droplets were kept in the 
beaker overnight to let the dispersed phase solvent evaporate. The particles were then 
washed three times with deionized water at 3,200 g for 5 minutes, frozen and lyophilized. 
 
Protein conjugation: To compare the difference between monodisperse PLGA particles 
and PLGA-PBAE blend microparticles for protein conjugation, the same EDC-NHS 
conjugation procedures with pre-degradation and non-simultaneous feeding of two 
proteins, as described in Chapter 3, were used. 
 
Characterization of microparticles: Microparticles were imaged under scanning electron 
microscopy (SEM) using a LEO/Zeiss Field-emission SEM. The sizes of microparticles 
were quantified manually using ImageJ[9]. 
 
Statistics: All experiments were performed with n = 5 replicates unless otherwise stated. 
Bar graphs indicate mean ± standard error of the mean. n.s. (not significant) indicates p > 
0.05, * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001, and **** 
indicates p ≤ 0.0001. All statistics were completed using statistical analysis software 
modules in GraphPad Prism 8 (GraphPad Software, Inc.; La Jolla, CA). For particle size 
measurements, a Student’s t-test was used to assess the difference between the particle 
sizes of PLGA microparticles and PLGA-PBAE microparticles. A Student’s t-test was used 
to evaluate the difference in protein conjugation between PLGA microparticles and PLGA-
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PBAE microparticles as well. In all cases, differences were considered significant if the p-
value of the test was less than 0.05. 
 
4.3 Results 
4.3.1 Water in oil emulsion through microfluidic flow focusing devices 
The microfluidic emulsions discussed in Chapter 3 using MFFDs were based on a 
single emulsion method, which limited the application of the fabricated monodisperse 
microparticles to the delivery of hydrophobic payloads that can be co-dissolved in the 
dispersed solvent phase. To broaden the application of the microfluidic flow focusing 
devices to deliver hydrophilic payloads such as proteins, we studied the application of 
MFFD to W/O emulsions. By enabling W/O emulsions, multiple devices could also be 
connected in series such that the first step, water droplets in oil (W/O), could then feed into 
the second step from Chapter 3 (O/W), to construct double emulsion microparticles 
(W/O/W) with excellent monodispersity.  
To investigate the capacity of MFFDs to produce water-in-oil droplets as the first 
step of double emulsion, we used 10% PVA solution as the dispersed phase and 
dichloromethane with Span 80 and Tween 80 as surfactants to prevent aggregation as the 
continuous phase in the MFFDs. The microfluidic device parameters were set to 5 mL/hr 
and 20 mL/hr for the dispersed phase and the continuous phase, respectively. Optical 
microscopy was used to image the generated water droplets, and sizes and polydispersity 
of micro-droplets were quantified. Using the above parameters, we successfully generated 




4.3.2 Monodisperse PLGA-PBAE blend microparticles 
As the initial EDC-NHS chemistry had a low conjugation efficiency for the PLGA 
microparticles, and recent work shows that poly-(beta-amino)-ester (PBAE)-PLGA blend 
polymeric particles can have improved in vivo efficacy for protein presentation[10], we 
investigated a 75% PLGA and 25% PBAE blend. The polymers were first dissolved in 
DCM as the dispersed phase in MFFDs to produce PLGA-PBAE blended monodisperse 
microparticles. The microfluidic device parameters were set to be the same as the 
production of monodisperse artificial antigen presenting cells described in Chapter 3. The 
monodisperse PLGA-PBAE microparticles were imaged via SEM, and the sizes and 
monodispersity were quantified by manual image analysis. There was not any significant 
difference between the sizes and monodispersity of PLGA-PBAE blend microparticles and 
PLGA microparticles (Figure 4.2 and Figure 4.3), which indicated that the devices were 
versatile to be used in the synthesis of monodisperse microparticles of different material 
composition and by opposite processing (O/W vs/ W/O) to achieve the same reproducible 
robust results. Monodisperse PLGA-PBAE blend microparticles showed an improved 
protein conjugation via EDC-NHS conjugation compared to bulk-prepared PLGA particles 
(Figure 4.4). Both microparticle types were made into aAPCs by following the same 
procedure that was previously optimized for PLGA aAPCs as discussed in Chapter 3.  
Namely, anti-CD28 protein conjugation was performed first for 3 hrs, followed by anti-
CD3 conjugation. While this sequential treatment was required for construction of PLGA 
aAPCs, it does not look like it is necessary for construction of PLGA-PBAE aAPCs. This 
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is because with PLGA-PBAE aAPCs, significantly more anti-CD28 antibodies conjugated 
to the surface of the PLGA-PBAE microparticles following the sequential addition protocol. 
A likely interpretation is that for cationic PBAE polymer, anionic protein can non-
specifically absorb preferentially to the surface[4], and the anti-CD28 antibodies that were 
added first were readily absorbed by the PBAE surface first, saturating the ability of PLGA-
PBAE to subsequently equitably absorb anti-CD3 proteins. This resulted in only a small 
portion of anti-CD3 proteins being conjugated to PLGA-PBAE microparticles. Notably, 
similar total protein levels on the surface of the particles were found with both the 
monodisperse PLGA microparticles and the monodisperse PLGA-PBAE microparticles. 
With further tuning of timing and feed-stock ratios, it is very likely that the monodisperse 
PLGA-PBAE microparticles can be fabricated with a 1:1 ratio of the two surface bound 
proteins just like the monodisperse PLGA microparticles. 
 
4.4 Conclusion and Discussion 
Through this study, we have broadened the application of the microfluidic devices 
from oil-in-water emulsions to water-in-oil emulsions, demonstrating their potential for 
more versatile production of monodisperse microparticles. The ability of MFFDs to 
fabricate PLGA-PBAE microparticles can broaden the application of the devices to gene 
delivery and protein delivery due to the inherent delivery characteristics of PBAEs and 
PLGA-PBAE blended polymers. The monodisperse PLGA-PBAE blended microparticles 
of defined size are promising for future investigation as artificial antigen presenting cells 
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and may have superior ability to bind and activate T cells compared to more conventional 
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Fig. 4.1. Optical microscopy images of water droplets in a hydrophobic phase 












Fig. 4.2. Size distribution of different microparticles. Microparticles made of PLGA 











Fig. 4.3. Size of different microparticles. The sizes of microparticles does not change 
significantly between monodisperse PLGA microparticles and PLGA-PBAE blended 









Fig. 4.4. Protein conjugation by EDC-NHS chemistry. Monodisperse microparticles 
made by MFFDs have higher conjugation efficiency for both of the proteins compared 
with microparticles made by bulk emulsion. Between the two monodisperse 
microparticles, there are more anti-CD28 antibodies on the PLGA-PBAE microparticles 







5.1 Future Directions 
Due to the COVID-19 pandemic, this study was halted at the stage of physical and 
chemical characterization of the monodisperse aAPCs. After the lab reopens, in vitro and 
in vivo functional tests will be conducted to examine T cell activation and proliferation by 
the monodisperse aAPCs. 
In this work, monodisperse PLGA microparticles with tunable sizes have been 
successfully developed through microfluidic flow focusing devices (MFFDs), and we have 
successfully demonstrated that monodisperse microparticles of cell-like size have the 
capacity to be functionalized as artificial antigen presenting cells (aAPCs). Our 
monodisperse microparticles exhibit increased protein conjugation efficiency compared 
with microparticles made by bulk emulsion and the capacity to release loaded hydrophobic 
immunoregulatory drugs in a controlled fashion over time. The scalable and robust 
fabrication procedure, the low variability between batches, the excellent control of particle 
size, and the excellent monodispersity at each of these particle sizes,  allows researchers 
the ability to better standardize the particle-based therapies including drug delivery devices 
and biomimetic aAPCs.   
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We have preliminarily shown the potential of the microfluidic devices to be a 
versatile particle synthesis platform for microparticles of different, payloads, materials, and 
processing conditions. We only just demonstrated that MFFDs can be used in W/O 
emulsion and O/W emulsion to generate the same type of monodisperse droplets and 
polymeric microparticles of the same monodisperse size. It would be interesting to explore 
in the future how putting these two validated devices and processes together in series could 
facilitate the generation of monodisperse double emulsion particles. Further, modified 
designs of MFFDs can be developed to do these two steps on a single chip rather than 
performing a traditional two-step bulk double emulsion process[1]. A microfluidic chip for 
double emulsion would be useful for monodispersity, reproducibility, and scalability, and 
also to improve efficiency and save on costs of expensive biological payloads such peptides, 
proteins and nucleic acids. 
The ability of MFFDs to fabricate monodisperse PLGA-PBAE microparticles 
broadens the application of the devices to synthesize gene delivery vectors and protein 
delivery vehicles. The efficacy of such monodisperse microparticles for gene delivery 
and/or protein delivery warrants further study. 
Overall, emulsions via microfluidic devices have the potential to provide a versatile 
technology for polymeric microparticle production and promote particle-based therapies in 
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